BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22173586)

  • 21. A fast track to personalized medicine?: whole-genome sequencing may lead to better cancer therapies.
    Nelson B
    Cancer Cytopathol; 2012 Oct; 120(5):283-4. PubMed ID: 23065928
    [No Abstract]   [Full Text] [Related]  

  • 22. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
    Cosler LE; Lyman GH
    Cancer Invest; 2009 Dec; 27(10):953-9. PubMed ID: 19909009
    [No Abstract]   [Full Text] [Related]  

  • 24. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Innovative therapy, early and cost-benefit assessment].
    Dierks C
    Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
    [No Abstract]   [Full Text] [Related]  

  • 26. Functional drug-gene interactions in lung cancer.
    Smida M; Nijman SM
    Expert Rev Mol Diagn; 2012 Apr; 12(3):291-302. PubMed ID: 22468819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The search for optimal response prediction in cancer leads to a personalized approach.
    Van Cutsem E; Ciardiello F
    Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
    [No Abstract]   [Full Text] [Related]  

  • 28. Communicating with patients about chemotherapy costs.
    de Lemos ML
    J Clin Oncol; 2007 May; 25(15):2142; author reply 2142. PubMed ID: 17513825
    [No Abstract]   [Full Text] [Related]  

  • 29. "It's the economy, stupid": strategies for improved cost containment in cancer treatment.
    Sleijfer S
    Clin Pharmacol Ther; 2014 Apr; 95(4):365-7. PubMed ID: 24646487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In an era of health reform: defining cost differences in current esophageal cancer management strategies and assessing the cost of complications.
    Kuppusamy M; Sylvester J; Low DE
    J Thorac Cardiovasc Surg; 2011 Jan; 141(1):16-21. PubMed ID: 21047648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost of health care services in the treatment of cancer.
    Ilbery PL
    Aust Fam Physician; 1978 Aug; 7(8):1062-74. PubMed ID: 101189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologics: Personalized drugs should cut care costs.
    Malik NN
    Nature; 2012 May; 485(7400):582. PubMed ID: 22660309
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of lung cancer: will financial issues become a criterion of choice?
    Vergnenegre A; Borget I; Chouaid C
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):273-5. PubMed ID: 23763524
    [No Abstract]   [Full Text] [Related]  

  • 35. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?
    Herbild L; Bech M; Gyrd-Hansen D; Christensen M; Werge T; Nielsen KA
    Scand J Public Health; 2011 Mar; 39(2):147-55. PubMed ID: 21257648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?
    Burock S; Meunier F; Lacombe D
    Eur J Cancer; 2013 Sep; 49(13):2777-83. PubMed ID: 23777742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted medications. New focus on companion tests.
    Reinke T
    Manag Care; 2012 Feb; 21(2):35-8. PubMed ID: 22393602
    [No Abstract]   [Full Text] [Related]  

  • 38. Soaring price of cancer drugs leads plans to new approaches.
    Sipkoff M
    Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
    [No Abstract]   [Full Text] [Related]  

  • 39. Health policy: Putting a price on cancer.
    Sullivan R; Aggarwal A
    Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
    [No Abstract]   [Full Text] [Related]  

  • 40. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.